Dare Bioscience, Inc. quarterly report, Q1 FY2022

Dare Bioscience, Inc. — Q1 2022 Form 10-Q

Business context and period. This unaudited quarterly report covers the three months ended March 31, 2022. Dare is a women’s health biopharmaceutical company whose business remains primarily research and development. XACIATO, its first FDA-approved product, was licensed to Organon for worldwide development and commercialization; U.S. commercial availability was expected in Q4 2022. The company had not generated revenue through the reporting period.

Financial performance and liquidity

MetricQ1 2022Q1 2021 / comparison
Revenue$0$0
Research and development expense$5.81 million$5.73 million, up 1%
General and administrative expense$2.57 million$1.94 million, up 32%
Total operating expenses$8.40 million$7.69 million, up 9%
Net loss$8.40 million$7.32 million; loss widened 15%
Loss per share, basic and diluted$0.10$0.16; weighted-average shares rose to 83.9 million from 44.5 million
Cash used in operating activities$12.34 million$8.38 million
Cash and cash equivalents, March 31$39.32 million$51.67 million at December 31, 2021
Working capital, March 31$31.4 million—

There were no product-sales margins to report. The company reported no material borrowing; balance-sheet liabilities included approximately $1.21 million of operating lease liabilities. The $367,285 PPP loan and accrued interest had been forgiven in 2021.

Material changes and notable items

  • Operating expenses increased $707,000 year over year. Higher G&A reflected increased professional services, stock compensation, personnel, and commercial-readiness costs. R&D was broadly flat: higher spending on the Sildenafil Cream Phase 2b trial and Ovaprene was offset by lower XACIATO, early-stage, and preclinical development costs.
  • Q1 2021 results included a $369,887 gain from PPP loan forgiveness; Q1 2022 had no comparable gain. Q1 2021 also included $11.37 million of financing cash inflows from equity and warrant activity; there were no financing proceeds in Q1 2022.
  • Cash declined by $12.36 million during Q1 2022. Increased prepaid expenses and lower deferred grant funding were among the operating cash uses.
  • After quarter-end, Dare sold approximately 751,000 shares through its ATM program for net proceeds of approximately $1.2 million through May 10, 2022.

Outlook, risks, and contingencies

  • Going concern and funding: Management stated that current cash was insufficient to cover working-capital needs and other liquidity requirements for at least 12 months from issuance of the financial statements, raising substantial doubt about the company’s ability to continue as a going concern. Additional capital is required; financing may be dilutive or unavailable on acceptable terms.
  • Spending outlook: Management expected 2022 R&D expense to increase significantly and potentially exceed twice 2021’s approximately $30.6 million. It expected 2022 G&A expense to rise approximately 20% versus 2021. The pace of development spending depends on available cash.
  • XACIATO/Organon: The March license agreement remained subject to closing conditions, including applicable antitrust review. Dare expected a $10 million non-refundable payment after effectiveness, a $2.5 million payment after first U.S. commercial sale, up to $180 million in additional milestones, and tiered double-digit royalties. The agreement also provides Organon termination rights. Payments and launch timing are not assured.
  • Pipeline: Dare targeted starting Ovaprene’s pivotal Phase 3 study during 2022, but FDA pre-submission discussions were ongoing. The company had paid $5.0 million of its $5.5 million CRADA commitment, with $0.5 million remaining. The Sildenafil Cream Phase 2b interim analysis was anticipated in 2022; timing for topline results would be updated afterward. DARE-HRT1’s Phase 1/2 study began in April 2022, with topline data anticipated in Q4 2022.
  • Grant funding: The DARE-LARC1 program had a Foundation grant award of up to $48.95 million through 2026, contingent on development and reporting milestones. Approximately $9.7 million was recorded as deferred grant funding at March 31, 2022; future funding is not guaranteed.
  • Other risks: The company cited clinical, regulatory, manufacturing, commercialization, third-party collaboration, intellectual-property, and capital-raising risks. COVID-19 had contributed to slower enrollment and development delays, although management said it had not materially adversely affected the business as a whole to date. No material changes to previously disclosed risk factors or material pending legal proceedings were reported.

Investor verification priorities

  • Confirm whether the Organon agreement became effective and whether the $10 million payment was received; monitor launch, first-sale milestone, royalties, and any termination developments.
  • Track cash burn, ATM share issuance, available financing, and whether the company can meet its stated funding needs beyond the next 12 months.
  • Verify actual 2022 R&D spending against management’s outlook and whether development programs or timelines change because of financing constraints.
  • Monitor FDA discussions and commencement of the Ovaprene pivotal trial, plus Sildenafil Cream interim-analysis timing and DARE-HRT1 study results.
  • Check the timing and conditions for Foundation grant disbursements and how deferred grant funding is used to support DARE-LARC1.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.